Valsartan for the treatment of heart failure

Bibliography

• LEVY D, KENCHAIAH S, LARSON MG et al.: Long-term trends in the incidence of and survival with heart failure. N Engl. I Med. (2002) 347(18):1397–1402.
   PubMed Web of Science ®Google Scholar
• HO KK, PINSKY JL, KANNEL WB, LEVY D: The epidemiology of heart failure: the Framingham Study. I Am. Coll. Cardiol (1993) 22(4 Suppl. A):6A–13A.
   Google Scholar
• COWIE MR, WOOD DA, COATS AJ et al.: Incidence and aetiology of heart failure a population-based study. Eur: Heart" (1999) 20(6):421–428.
   PubMed Web of Science ®Google Scholar
• PULIGNANO G, DEL SINDACO D, TAVAZZI L et al.: Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am. Heart J. (2002) 143(1):45–55.
   PubMedGoogle Scholar
• CLELAND JG, SWEDBERG K, FOLLATH F et al.: The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Ear: Heart J. (2003) 24(5):442–463.
   Google Scholar
• DI LENARDA A, SCHERILLO M, MAGGIONI AP et al: Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds - The TEMISTOCLE study. Am. Heart j (2003) 146:e12.
   PubMedGoogle Scholar
• UNGER T: The role of the renin-angiotensin system in the development of cardiovascular disease. Am. J. Cardiol (2002) 89(2A):3A–9A.
   Google Scholar
• HORIUCHI M, AKISHITA M, DZAU VJ: Recent progress in angiotensin II Type 2 receptor research in the cardiovascular system. Hypertension (1999) 33:613–621.
   PubMed Web of Science ®Google Scholar
• STROTH U, UNGER T: The renin-angiotensin system and its receptors. Cardiovasc. Pharmacol (1999) 33\(Suppl. 1):S21–S28.
   Google Scholar
• DE MELLO WC, DANSER AH: Angiotensin II and the heart: on the intracrine renin-angiotensin system. Hypertension (2000) 35(6):1183–1188.
   PubMed Web of Science ®Google Scholar
• CAREY RM, WANG ZQ, SIRAGY HM: Role of the angiotensin Type 2 receptor in the regulation of blood pressure and renal function. Hypertension (2000) 35(1 Pt 2):155–163.
   Google Scholar
• KAJSTURAJ, CIGOLA E, MALHOTRA A et al.: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. I Molec. Cardiol (1997) 29:859–870.
   PubMedGoogle Scholar
• DE ANGELIS N, FIORDALISO F, LATINI R et al.: Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J. Ma Cell Cardiol (2002) 34:1655–1665.
   PubMedGoogle Scholar
• MATSUBARA H: Pathophysiological role of angiotensin II Type 2 receptor in cardiovascular and renal diseases. Circ. Res. (1998) 83:1182–1191.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of the role of AT2 receptors.
   Google Scholar
• BLACK HR, GRAFF A, SHUTE D et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J. Hum. Hypertens. (1997) 11(8):483–489.
   PubMed Web of Science ®Google Scholar
• HOLWERDA NJ, FOGARI R, ANGELI P et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. Hypertens. (1996) 14(9):1147–1151.
   Google Scholar
• MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. (2000) 321(72701440–1444.
   Google Scholar
• NEUTEL JM, FRISHMAN WH, OPARIL S, PAPADEMITRIOU V, GUTHRIE G: Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am. J. Titer. (1999) 6(3):161–166.
   Google Scholar
• ELLIOTT WJ: Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. J. Hum. Hypertens. (1999) 13(6):413–417.
   PubMedGoogle Scholar
• DE GASPARO M, WHITEBREAD S: Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept. (1995) 59(3):303–311.
   PubMedGoogle Scholar
• LORELL BH: Role of angiotensin AT1, and AT2 receptors in cardiac hypertrophy and disease. Am. J. Cardiol (1999) 83(12A):48H–52H.
   Google Scholar
• WAGENAAR LJ, VOORS AA, BUIKEMA H, VAN GILST WH: Angiotensin receptors in the cardiovascular system. Can. J. Cardiol (2002) 18(12):1331–1339.
   PubMedGoogle Scholar
• DE GASPARO M, HESS P, NUESSLEIN-HILDESHEIM B, BRUNEVAL P, CLOZEL JP: Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction." Renin Angiotensin Aldosterone Syst. (2000) 1(2):151–158.
   Google Scholar
• MANCINI GB: Emerging role of angiotensin II Type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. Can. J. Cardiol (2002) 18(12):1309–1316.
   PubMedGoogle Scholar
• MARKHAM A, GOA KL: Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs (1997) 54(2):299–311.
   Google Scholar
• THURMANN PA: Valsartan: a novel angiotensin Type 1 receptor antagonist. Expert Opin. Pharmacother. (2000) 1(2)337–350.
   Google Scholar
• CRISCIONE L, BRADLEY WA, BUHLKMAYER P et al.: Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc. Drug Rev. (1995) 13:230–250.
   Web of Science ®Google Scholar
• PITT B, SEGL R, MARTINEZ FA et al: ELITE Study Investigators, Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SE GAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582–1587.
   Google Scholar
• KAWAMURA M, IMANASHI M, MATSUSHIMA Y, ITO K, HIRAMORI K: Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin. Exp. Pharmacol Physiol (1992) 19:547–553.
   PubMed Web of Science ®Google Scholar
• JORDE UP, ENNEZAT PV, LISKER J et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation (2000) 101:844–846.
   PubMed Web of Science ®Google Scholar
• ZORNOFF LA, PAIVA SA, MATSUBARA BB, MATSUBARA LS, SPADARO J: Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor on ventricular remodeling after myocardial infarction in rats. J. Cardiovasc. Pharmacol Titer. (2000) 5(3):203–209.
   PubMedGoogle Scholar
• BURNIER M: Angiotensin II Type 1 receptor blockers. Circulation (2001) 103(6):904–912.
   PubMed Web of Science ®Google Scholar
• PATTERSON JH: Angiotensin II receptor blockers in heart failure. Pharmacotherapy (2003) 23(2):173–182.
   PubMedGoogle Scholar
• PETERSON RC, DUNLAP ME: Angiotensin II receptor blockers in the treatment of heart failure. Congest. Heart Fail. (2002) 8(5):246–250.
   PubMedGoogle Scholar
• DICKSTEIN K: ELITE II and Val-HeFT are different trials: together what do they tell us? Carr. Control Trials Cardiovasc. Med. (2001) 2(5):240–243.
   PubMedGoogle Scholar
• HAMROFF G, KATZ SD, MANCINI D et al.: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 99(8):990–992.
   PubMedGoogle Scholar
• MCKELVIE RS, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation (1999) 100:1056–1064.
   PubMed Web of Science ®Google Scholar
• BARUCH L, ANAND I, COHEN IS, ZIESCHE S, JUDD D, COHN JN: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation (1999) 99(20):2658–2664.
   Google Scholar
• COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. I Med. (2001) 345(23):1667–1675.
   PubMed Web of Science ®Google Scholar
• ••The main results of Val-HeFT.
   Google Scholar
• COHN JN, TOGNONI G, GLAZER R, SPORMANN D: Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur: Heart Fail. (2000) 2(4):439–446.
   PubMedGoogle Scholar
• COHN JN, TOGNONI G, GLAZER RD, SPORMANN D, HESTER A: Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J. Card. Fail. (1999) 5(2):155–160.
   PubMed Web of Science ®Google Scholar
• TAVAZZI L, PINA I, CHIANG YT et al: Association of quality of life with improved clinical outcomes: results from the valsartan heart failure trial. I Am. Coll. Cardiol. (2002) 39(5):167A.
   Google Scholar
• FRANCIS GS, COHN JN, JOHNSON G, RECTOR TS, GOLDMAN S, SIMON A, FOR THE V-HEFT VA COOPERATIVE STUDIES GROUP: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation (1993) 87(VI) 40–48.
   Google Scholar
• •One of the earlier and more convincing pieces of evidence of the relationship between survival and neurohormonal activation in HE and the higher efficacy of ACEI in patients with more neurohormonal activation.
   Google Scholar
• KOGLIN J, PEHLIVANLI S, SCHWAIBLMAIR M, VOGESER M, CREMER P, VON SCHEIDT W: Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure., " Am. Coll Cardiol. (2001) 38:1934–1941.
   Google Scholar
• BENEDICT CR, SHELTON B, JOHNSTONE DE et al.: Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation (1996) 94:690–697.
   PubMed Web of Science ®Google Scholar
• LATINI R, MASSON S, DE ANGELIS N, ANAND I: Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. J. Card. Fail. (2002) 8(5):288–299.
   PubMedGoogle Scholar
• LATINI R, MASSON S, ANAND I et al: Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2002) 106(19):2454–2458.
   PubMed Web of Science ®Google Scholar
• •Valsartan durably reduces neurohormonal activation in HF patients randomised in Val-HeFT: evidence of a neurohormonal effect of a drug based on 4300 patients.
   Google Scholar
• ANAND IS, FISHER LD, CHIANG YT et al.: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 107(9):1278–1283.
   PubMed Web of Science ®Google Scholar
• •Elevated baseline BNP and increases in BNP over time are important predictors of outcome in HF patients.
   Google Scholar
• COHN JN, ANAND IS, LATINI R et al.: Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure. Results from the Valsartan Heart Failure Trial. Circulation (2003) 108:r61–r64.
   Google Scholar
• •Valsartan durably reduces plasma aldosterone in patients with HE
   Google Scholar
• WONG M, STASZEWSKY L, LATINI R et al.: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. I Am. Coll Cardiol (2002) 40(5):970–975.
   PubMed Web of Science ®Google Scholar
• •Valsartan improves left ventricular structure and function in HF patients randomised in Val-HeFT: evidence based on 5000 patients.
   Google Scholar
• WONG M, STASZEWSKY L, ANAND I, FELICIANO N, HESTER A, COHN JN: Stratification of baseline left ventricular dimensions and ejection fraction determines response to valsartan in heart failure. Val-HeFT echocardiographic study. Circulation (2002) 106(19) (Suppl.):11–5–11–2.
   Google Scholar
• MASSIE BM: Neurohormonal blockade in chronic heart failure. How much is enough? Can there be too much?" Am. Coll. Cardiol. (2002) 39(1):79–82.
   Google Scholar
• PITT B, REMME W, ZANNAD F et al. FOR THE EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl. I Med. (2003) 348:1309–1321.
   PubMed Web of Science ®Google Scholar
• ••First proof that aldosterone receptorblockade reduces mortality and morbidity in patients with LV dysfunction and HF after MI.
   Google Scholar
• MCMURRAY JJV, OSTERGREN J, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362(9386):767–771.
   PubMedGoogle Scholar
• ••Candesartan reduces cardiovascularmortality and morbidity in patients with HF taking ACEIs.
   Google Scholar
• MCKELVIE RS, ROULEAU JL, WHITE M et al.: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur: Heart J. (2003) 24:1727–1734.
   Google Scholar
• MAGGIONI AP, ANAND I, GOTTLIEB SO, LATINI R, TOGNONI G, COHN JN: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. (2002) 40(8):1414–1421.
   PubMed Web of Science ®Google Scholar
• ••A post hoc analysis on 366 patients onwhich the FDA based their indication for valsartan in patients with HF intolerant to ACEIs.
   Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian
   Google Scholar
• •• Enalapril Survival Study (CONSENSUS). New Engl. J. Med. (1987) 316:1429–1435.
   Google Scholar
• BART BA, ERTL G, HELD P et al: Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur. Heart j (1999) 20(101182–1190.
   Google Scholar
• GRANGER CB, McMURRAY JJV, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM- Alternative trial. Lancet (2003) 362(9380772–776. Candesartan reduces cardiovascular mortality and morbidity in patients with HF intolerant to ACEIs.
   Google Scholar
• PFEFFER MA, MCMURRAY JJV, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Engl. I Med. (2003) 349:1893–1906.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, SWEDBERG K, GRANGER CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 362(9386):759–766. Candesartan reduced cardiovascular deaths and hospital admissions for HF in this large clinical trial.
   Google Scholar